Research & Literature

How I treat hyperleukocytosis in acute myeloid leukemia.

Röllig C, Ehninger G

Blood 2015; (125(21)):3246-52 doi:10.1182/blood-2014-10-551507.

Natural course and biology of CML.

Chereda B, Melo JV

Annals of hematology 2015; (94 Suppl 2()):S107-21 doi:10.1007/s00277-015-2325-z.

A review of the European LeukemiaNet recommendations for the management of CML.

Baccarani M, Castagnetti F, Gugliotta G, Rosti G

Annals of hematology 2015; (94 Suppl 2()):S141-7 doi:10.1007/s00277-015-2322-2.

Myeloproliferative Neoplasms: A Contemporary Review.

Tefferi A, Pardanani A

JAMA oncology 2015; (1(1)):97-105 doi:10.1001/jamaoncol.2015.89.

Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?

Iurlo A, Orsi E, Cattaneo D, et al.

Oncotarget 2015; (6(32)):33944-51 doi:10.18632/oncotarget.5580.

Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study.

Hochhaus A, Rosti G, Cross NC, et al.

Leukemia 2016; (30(1)):57-64 doi:10.1038/leu.2015.270.

Leukostasis in Children and Adolescents with Chronic Myeloid Leukemia: Japanese Pediatric Leukemia/Lymphoma Study Group.

Kurosawa H, Tanizawa A, Tono C, et al.

Pediatric blood & cancer 2016; (63(3)):406-11 doi:10.1002/pbc.25803.

Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials.

Sasaki K, Strom SS, O'Brien S, et al.

The Lancet. Haematology 2015; (2(5)):e186-93.

Young age and high cost are associated with future preference for stopping tyrosine kinase inhibitor therapy in Chinese with chronic myeloid leukemia.

Jiang Q, Liu ZC, Zhang SX, Gale RP

Journal of cancer research and clinical oncology 2016; (142(7)):1539-47 doi:10.1007/s00432-016-2159-7.

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.

Steegmann JL, Baccarani M, Breccia M, et al.

Leukemia 2016; (30(8)):1648-71 doi:10.1038/leu.2016.104.

Practical recommendation for rash and diarrhea management in Indian patients treated with tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.

Parikh P, Prabhash K, Naik R, et al.

Indian journal of cancer 2016; (53(1)):87-91 doi:10.4103/0019-509X.180863.

Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population.

Bower H, Björkholm M, Dickman PW, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016; (34(24)):2851-7 doi:10.1200/JCO.2015.66.2866.

Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions.

Bhalla S, Tremblay D, Mascarenhas J

Clinical lymphoma, myeloma & leukemia 2016; (16(9)):488-494 doi:10.1016/j.clml.2016.06.012.

Molecular monitoring in chronic myeloid leukemia-how low can you go?

Branford S

Hematology. American Society of Hematology. Education Program 2016; (2016(1)):156-163 doi:10.1182/asheducation-2016.1.156.

Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients.

Arun AK, Senthamizhselvi A, Mani S, et al.

International journal of laboratory hematology 2017; (39(3)):235-242 doi:10.1111/ijlh.12616.

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study.

Hochhaus A, Masszi T, Giles FJ, et al.

Leukemia 2017; (31(7)):1525-1531 doi:10.1038/leu.2017.63.

Clinical impact of pretransplant use of multiple tyrosine kinase inhibitors on the outcome of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia.

Kondo T, Nagamura-Inoue T, Tojo A, et al.

American journal of hematology 2017; (92(9)):902-908 doi:10.1002/ajh.24793.

BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.

Cuellar S, Vozniak M, Rhodes J, et al.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2018; (24(6)):433-452 doi:10.1177/1078155217710553.

Pulmonary arterial hypertension induced by tyrosine kinase inhibitors.

Weatherald J, Chaumais MC, Montani D

Current opinion in pulmonary medicine 2017; (23(5)):392-397 doi:10.1097/MCP.0000000000000412.

Minimal Residual Disease Eradication in CML: Does It Really Matter?

Tantravahi SK, Guthula RS, O'Hare T, Deininger MW

Current hematologic malignancy reports 2017; (12(5)):495-505 doi:10.1007/s11899-017-0409-7.

Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia.

Jiang Q, Wang H, Yu L, Gale RP

Journal of cancer research and clinical oncology 2017; (143(12)):2619-2630 doi:10.1007/s00432-017-2517-0.

First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI.

Saglio G, Jabbour E

Leukemia & lymphoma 2018; (59(7)):1523-1538 doi:10.1080/10428194.2017.1379074.

Inadequate response to imatinib treatment in chronic myeloid leukemia due to a drug interaction with phenytoin.

Osorio S, Escudero-Vilaplana V, Gómez-Centurión I, et al.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2019; (25(3)):694-698 doi:10.1177/1078155217743565.

Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.

Soderquist CR, Ewalt MD, Czuchlewski DR, et al.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2018; (31(5)):690-704 doi:10.1038/modpathol.2017.182.

Late Emergence of an Imatinib-Resistant ABL1 Kinase Domain Mutation in a Patient with Chronic Myeloid Leukemia.

Crampe M, Andrews C, Fortune A, Langabeer SE

Case reports in hematology 2017; (2017()):3548936 doi:10.1155/2017/3548936.

Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring.

Jabbour E, Kantarjian H

American journal of hematology 2018; (93(3)):442-459 doi:10.1002/ajh.25011.

Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.

Mahon FX, Boquimpani C, Kim DW, et al.

Annals of internal medicine 2018; (168(7)):461-470 doi:10.7326/M17-1094.

Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study.

Ross DM, Masszi T, Gómez Casares MT, et al.

Journal of cancer research and clinical oncology 2018; (144(5)):945-954 doi:10.1007/s00432-018-2604-x.

Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.

Cortes JE, Kim DW, Pinilla-Ibarz J, et al.

Blood 2018; (132(4)):393-404 doi:10.1182/blood-2016-09-739086.

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.

Saussele S, Richter J, Guilhot J, et al.

The Lancet. Oncology 2018; (19(6)):747-757 doi:10.1016/S1470-2045(18)30192-X.

Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?

Osorio S, Escudero-Vilaplana V, Gómez-Centurión I, et al.

Annals of hematology 2018; (97(11)):2089-2098 doi:10.1007/s00277-018-3413-7.

[Chronic myeloid leukemia: state-of-the-art management].

Takahashi N

[Rinsho ketsueki] The Japanese journal of clinical hematology 2018; (59(6)):747-754 doi:10.11406/rinketsu.59.747.

Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells.

Ross DM, Pagani IS, Shanmuganathan N, et al.

Leukemia 2018; (32(12)):2572-2579 doi:10.1038/s41375-018-0264-0.

A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors.

Zulbaran-Rojas A, Lin HK, Shi Q, et al.

Cancer medicine 2018; (7(11)):5457-5469 doi:10.1002/cam4.1808.

Genomic amplification of BCR-ABL1 fusion gene and its impact on the disease progression mechanism in patients with chronic myelogenous leukemia.

Chandran RK, Geetha N, Sakthivel KM, et al.

Gene 2019; (686()):85-91 doi:10.1016/j.gene.2018.11.005.

Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system.

Kizaki M, Takahashi N, Iriyama N, et al.

International journal of hematology 2019; (109(4)):426-439 doi:10.1007/s12185-019-02613-1.

Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia.

Molica M, Scalzulli E, Colafigli G, et al.

Therapeutic advances in hematology 2019; (10()):2040620719826444 doi:10.1177/2040620719826444.

Impact of Additional Chromosomal Aberrations on the Disease Progression of Chronic Myelogenous Leukemia.

Krishna Chandran R, Geetha N, Sakthivel KM, et al.

Frontiers in oncology 2019; (9()):88 doi:10.3389/fonc.2019.00088.

Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry).

Möbius S, Schenk T, Himsel D, et al.

Journal of cancer research and clinical oncology 2019; (145(6)):1645-1650 doi:10.1007/s00432-019-02910-6.

Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry.

Lübking A, Dreimane A, Sandin F, et al.

Bone marrow transplantation 2019; (54(11)):1764-1774 doi:10.1038/s41409-019-0513-5.

Predictive value of early molecular response for deep molecular response in chronic phase of chronic myeloid leukemia.

Wang R, Cong Y, Li C, et al.

Medicine 2019; (98(15)):e15222 doi:10.1097/MD.0000000000015222.

Coexistence of breakpoint cluster region-Abelson1 rearrangement and Janus kinase 2 V617F mutation in chronic myeloid leukemia: A case report.

Shi XB, Jiang JF, Jin FX, Cheng W

World journal of clinical cases 2019; (7(9)):1087-1092 doi:10.12998/wjcc.v7.i9.1087.

Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia With Losing Major Molecular Response as a Definition for Molecular Relapse: A Systematic Review and Meta-Analysis.

Chen KK, Du TF, Xiong PS, et al.

Frontiers in oncology 2019; (9()):372 doi:10.3389/fonc.2019.00372.

[Recommendations from the French CML Study Group (Fi-LMC) for BCR-ABL1 kinase domain mutation analysis in chronic myeloid leukemia].

Cayuela JM, Chomel JC, Coiteux V, et al.

Bulletin du cancer 2020; (107(1)):113-128 doi:10.1016/j.bulcan.2019.05.011.

Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study.

Soverini S, Bavaro L, De Benedittis C, et al.

Blood 2020; (135(8)):534-541 doi:10.1182/blood.2019002969.

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.

Hochhaus A, Baccarani M, Silver RT, et al.

Leukemia 2020; (34(4)):966-984 doi:10.1038/s41375-020-0776-2.

High-risk additional chromosomal abnormalities at low blast counts herald death by CML.

Hehlmann R, Voskanyan A, Lauseker M, et al.

Leukemia 2020; (34(8)):2074-2086 doi:10.1038/s41375-020-0826-9.

Optimizing patient selection for treatment-free remission.

Rausch CR, Paul S

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2020; (26(5)):1220-1224 doi:10.1177/1078155220925167.

Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study.

Hochhaus A, Gambacorti-Passerini C, Abboud C, et al.

Leukemia 2020; (34(8)):2125-2137 doi:10.1038/s41375-020-0915-9.

Multi-center observational study on the adherence, quality of life, and adverse events in lung cancer patients treated with tyrosine kinase inhibitors.

Rosentreter J, Alt J, Fried M, et al.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2021; (27(5)):1147-1158 doi:10.1177/1078155220946381.

ABL Kinase Domain Mutations in Iranian Chronic Myeloid Leukemia Patients with Resistance to Tyrosine Kinase Inhibitors.

Shojaei M, Rezvani H, Azarkeivan A, Poopak B

Laboratory medicine 2021; (52(2)):158-167 doi:10.1093/labmed/lmaa052.

Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

Deininger MW, Shah NP, Altman JK, et al.

Journal of the National Comprehensive Cancer Network : JNCCN 2020; (18(10)):1385-1415.

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?

Atallah E, Schiffer CA

Haematologica 2020; (105(12)):2738-2745 doi:10.3324/haematol.2019.242891.

The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis.

Shoukier M, Borthakur G, Jabbour E, et al.

Haematologica 2021; (106(11)):2853-2858 doi:10.3324/haematol.2020.260125.

Variables associated with self-reported anxiety and depression symptoms in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy.

Shi D, Li Z, Li Y, Jiang Q

Leukemia & lymphoma 2021; (62(3)):640-648 doi:10.1080/10428194.2020.1842397.

Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network.

Schäfer V, White HE, Gerrard G, et al.

Journal of cancer research and clinical oncology 2021; (147(10)):3081-3089 doi:10.1007/s00432-021-03569-8.

Philadelphia chromosome positive chronic myeloid leukemia with 5q deletion at diagnosis.

Haidary AM, Ahmed ZA, Abdul-Ghafar J, et al.

Molecular cytogenetics 2021; (14(1)):16 doi:10.1186/s13039-021-00539-0.

Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions.

Osman AEG, Deininger MW

Blood reviews 2021; (49()):100825 doi:10.1016/j.blre.2021.100825.

Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update.

Hughes TP, Clementino NCD, Fominykh M, et al.

Leukemia 2021; (35(6)):1631-1642 doi:10.1038/s41375-021-01260-y.

Relevance of treatment-free remission recommendations in chronic phase chronic leukemia patients treated with frontline tyrosine kinase inhibitors.

Etienne G, Faberes C, Bauduer F, et al.

Cancer medicine 2021; (10(11)):3635-3645 doi:10.1002/cam4.3921.

Early prediction of stable MR4.5 by depth of molecular response at 6 months in patients with chronic myeloid leukemia treated with frontline imatinib.

Nee A, Lipton JH, Kim DDH

Leukemia & lymphoma 2022; (63(1)):162-169 doi:10.1080/10428194.2021.1961234.

Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial.

Cortes J, Apperley J, Lomaia E, et al.

Blood 2021; (138(21)):2042-2050 doi:10.1182/blood.2021012082.

Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panel.

Pavlovsky C, Abello Polo V, Pagnano K, et al.

Blood advances 2021; (5(23)):4855-4863 doi:10.1182/bloodadvances.2020003235.

Severe pleural effusion associated with nilotinib for chronic myeloid leukaemia: cross-intolerance with tyrosine kinase inhibitors.

Satoh K, Morisawa S, Okuyama M, Nakae H

BMJ case reports 2021; (14(9)) doi:10.1136/bcr-2021-243671.

Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome‒positive leukemias.

Kota V, Brümmendorf TH, Gambacorti-Passerini C, et al.

Leukemia research 2021; (111()):106690 doi:10.1016/j.leukres.2021.106690.

Dasatinib-Induced Colitis with Rectal Sparing in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy: Case Report.

Maat Z, Mushtaq K, Yassin MA

Case reports in oncology 2021; (14(3)):1441-1446 doi:10.1159/000516794.

BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia.

Amarante-Mendes GP, Rana A, Datoguia TS, et al.

Pharmaceutics 2022; (14(1)) doi:10.3390/pharmaceutics14010215.

Navigating Challenges in Monitoring Chronic Myeloid Leukemia with Multiple BCR-ABL1 Transcripts.

Smith BM, Brewer D, Druker BJ, Braun TP

Case reports in oncology 2021; (14(3)):1707-1711 doi:10.1159/000520400.

Impact of BCR-ABL1 Transcript Type on Outcome in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors: A Pairwise and Bayesian Network Meta-Analysis.

Chen K, Ruan Y, Tian K, et al.

Frontiers in oncology 2022; (12()):841546 doi:10.3389/fonc.2022.841546.

Contribution of BCR-ABL molecular variants and leukemic stem cells in response and resistance to tyrosine kinase inhibitors: a review.

Al Hamad M

F1000Research 2021; (10()):1288 doi:10.12688/f1000research.74570.2.

Vertebral artery stenosis predicts cerebrovascular diseases following radiotherapy for nasopharyngeal carcinoma.

Yeh CF, Chin YC, Hung W, et al.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2022; (30(7)):5821-5830 doi:10.1007/s00520-022-07011-8.

The Global Burden of Leukemia and Its Attributable Factors in 204 Countries and Territories: Findings from the Global Burden of Disease 2019 Study and Projections to 2030.

Du M, Chen W, Liu K, et al.

Journal of oncology 2022; (2022()):1612702 doi:10.1155/2022/1612702.

Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study.

White HE, Salmon M, Albano F, et al.

Leukemia 2022; (36(7)):1834-1842 doi:10.1038/s41375-022-01607-z.

Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring.

Jabbour E, Kantarjian H

American journal of hematology 2022; (97(9)):1236-1256 doi:10.1002/ajh.26642.

Comparison of molecular responses and outcomes between BCR::ABL1 e14a2 and e13a2 transcripts in chronic myeloid leukemia.

Su YJ, Kuo MC, Chen TY, et al.

Cancer science 2022; (113(10)):3518-3527 doi:10.1111/cas.15501.

Transplantation in CML in the TKI era: who, when, and how?

Niederwieser C, Kröger N

Hematology. American Society of Hematology. Education Program 2022; (2022(1)):114-122 doi:10.1182/hematology.2022000329.

Intracerebral hemorrhage as the first symptomatic manifestation of chronic myeloid leukemia (chronic phase): A case report and literature review.

Ashraf M, Naseeruddin G, Zahra SG, et al.

Surgical neurology international 2023; (14()):5 doi:10.25259/SNI_897_2022.

Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention.

Shanmuganathan N, Wadham C, Shahrin N, et al.

Haematologica 2023; (108(9)):2380-2395 doi:10.3324/haematol.2022.282184.

Cancer Therapy-Related Pulmonary Hypertension: A Review of Mechanisms and Implications for Clinical Practice.

Gürdoğan M, Demir M, Yalta K, Gülertop Y

Anatolian journal of cardiology 2023; (27(6)):299-307 doi:10.14744/AnatolJCardiol.2023.3013.

Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results.

Gener-Ricos G, Haddad FG, Sasaki K, et al.

Clinical lymphoma, myeloma & leukemia 2023; (23(10)):742-748 doi:10.1016/j.clml.2023.05.009.

Comparison of cutaneous adverse events between second-generation tyrosine kinase inhibitors and imatinib for chronic myeloid leukemia: a systematic review and meta-analysis.

Cha SH, Kim K, Song YK

Acta oncologica (Stockholm, Sweden) 2023; (62(12)):1767-1774 doi:10.1080/0284186X.2023.2263152.

Resistance mutations in CML and how we approach them.

Soverini S

Hematology. American Society of Hematology. Education Program 2023; (2023(1)):469-475 doi:10.1182/hematology.2023000447.

Ponatinib vs. asciminib in post-second-generation tyrosine kinase inhibitor therapy for chronic-phase chronic myeloid leukemia: a matching-adjusted indirect comparison.

Garcia-Gutierrez V, Huang F, Ashaye A, et al.

Frontiers in oncology 2024; (14()):1455378 doi:10.3389/fonc.2024.1455378.

Advanced-Stage Chronic Myeloid Leukemia: Options for Difficult Treatment Situations.

Atallah E, Deininger M

Drugs 2025; (85(1)):41-50 doi:10.1007/s40265-024-02108-2.

Asciminib: the tyrosine kinase inhibitor with a unique mechanism of action.

Jain AG, Cortes JE

Expert opinion on pharmacotherapy 2025; (26(6)):677-684 doi:10.1080/14656566.2025.2480762.

Chronic Myeloid Leukemia: A Review.

Jabbour E, Kantarjian H

JAMA 2025; (333(18)):1618-1629 doi:10.1001/jama.2025.0220.

Which Is the Best Tyrosine Kinase Inhibitor for Newly Diagnosed Chronic Myelogenous Leukemia?

Shanmuganathan N, Osborn M, Hughes TP

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2025; (45(3)):e473082 doi:10.1200/EDBK-25-473082.

Living with chronic myelogenous leukemia in rural communities: Exploring factors related to tyrosine kinase inhibitors adherence with a mixed methods approach.

Sheng J, Heiney SP, Wickersham KE, et al.

The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association 2025; (41(2)):e70028 doi:10.1111/jrh.70028.

Structure and Dynamics of the ABL1 Tyrosine Kinase and Its Important Role in Chronic Myeloid Leukemia.

Irgit A, Kamıs R, Sever B, et al.

Archiv der Pharmazie 2025; (358(5)):e70005 doi:10.1002/ardp.70005.

Uncommon phenotypes of BCR::ABL1-positive chronic myelogenous leukemia.

Jajosky AN, Lichtman MA

Haematologica 2025; (110(9)):1912-1920 doi:10.3324/haematol.2025.287792.

Clinical features and treatment response to TKIs in chronic myeloid leukemia patients with atypical BCR::ABL1 transcripts.

Wang H, Han C, Gong B, et al.

Leukemia research 2025; (155()):107733 doi:10.1016/j.leukres.2025.107733.

Adverse reactions of dasatinib in pediatric acute lymphoblastic leukemia: a retrospective comparative cohort study.

Yu LT, Xue Q, Feng Q, et al.

Translational pediatrics 2025; (14(11)):3002-3010 doi:10.21037/tp-2025-403.

Multidisciplinary Rehabilitation for Severe Respiratory Failure Due to Dasatinib-Induced Pulmonary Toxicity: A Case Report.

Nozaki K, Hamazaki N, Takeshita Y, et al.

The American journal of case reports 2026; (27()):e953380 doi:10.12659/AJCR.953380.

Intraoperative Collapse During First-Trimester Abortion: Hyperleukocytosis Crisis, Thrombotic Pulmonary Embolism, or Amniotic Fluid Embolism?

Wen T, Zhang Y, Zhong Y, Song S

International journal of women's health 2026; (18()):604225 doi:10.2147/IJWH.S604225.